The global aspirin exacerbated respiratory disease market size is expected to reach US$ 8.7 Billion in 2032 and exhibit growth at a CAGR of 4.9% in the forecast period from 2022 to 2032. As per the report, sales of treatment options for aspirin exacerbated respiratory disease is likely to exceed US$ 3.1 Billion in 2022. The increasing number of research and development activities to discover novel treatment options are anticipated to boost the market.
| Report Attribute | Details |
| Aspirin Exacerbated Respiratory Disease Market Estimated Base Year Value (2021) | US$ 2.5 Billion |
| Aspirin Exacerbated Respiratory Disease Market Expected Market Value (2022) | US$ 3.1 Billion |
| Aspirin Exacerbated Respiratory Disease Market Anticipated Forecast Value (2032) | US$ 8.7 Billion |
| Aspirin Exacerbated Respiratory Disease Market Projected Growth Rate (2022-2032) | 4.9% CAGR |
Aspirin-exacerbated respiratory disease or Samter’s Triad is a chronic medical condition that includes three clinical features, namely, sensitivity to aspirin, sinus disease with recurrent nasal polyps, and asthma. Signs and symptoms of this disease do not usually show up until an individual reaches their 30s or 40s.
Some of the signs and symptoms include sneezing, difficulty breathing, runny nose, coughing, or wheezing. Some people living with aspirin-exacerbated respiratory disease often get these types of reactions if they drink alcoholic beverages, such as wine or beer.
There is no specific test to diagnose the disease. Laboratory tests, such as blood tests help in looking for higher than normal levels of eosinophils, which are white blood cells. Healthcare professionals often recommend urine tests to observe inflammatory substances and elevated leukotrienes in the body.
Increasing prevalence of breathing problems, such as asthma is anticipated to augur well for the global market. As per the World Health Organization (WHO), nearly 262 million people were living with asthma in 2019 and it had caused 461000 deaths. These numbers are projected to grow at a fast pace, thereby pushing the demand for aspirin exacerbated respiratory disease treatment options.
Moreover, surging awareness programs conducted by government agencies to educate the masses about the signs and symptoms of this disease is set to drive the market. Rising healthcare expenditure in both developed and developing countries across the globe is another vital factor that is likely to fuel the market.
The diagnosis of aspirin exacerbated respiratory disease can often be delayed unless healthcare professionals have experience or expertise in recognizing and treating it. Thus, the lack of skilled healthcare professionals across emerging economies is projected to hamper the aspirin exacerbated respiratory disease market growth in future years.
North America is likely to remain at the forefront by procuring the largest aspirin exacerbated respiratory disease market share in the upcoming years. The presence of numerous large-scale pharmaceutical companies in the U.S. and Canada is projected to augur well for the regional market.
The increasing consumption of zileuton (Zyflo) or montelukast (Singulair) to block the effects of leukotrienes across North America is also set to propel the market. In addition to that, patients are increasingly adopting medications, such as inhaled corticosteroids to manage asthma and it is further expected to augment the market.
Asia Pacific is likely to remain in the second position followed by North America in terms of share during the evaluation period. Rising prevalence of pollution induced asthma and the ongoing development of healthcare infrastructure in China and India are anticipated to drive the sales of aspirin exacerbated respiratory disease treatment medications.
Besides, the entry of international pharmaceutical companies in these countries owing to the availability of low-cost labor and raw material is expected to foster growth. The availability of innovative injectable medications, commonly called biologics, would also contribute to the regional market growth.
Some of the renowned companies operating in the global aspirin exacerbated respiratory disease market include Apotex Corporation, Pfizer Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Cadila Pharmaceuticals among others.
Majority of the leading companies present in the global market are increasingly focusing on mergers and acquisitions, collaborations, and joint ventures to co-develop novel products and strengthen their positions. Meanwhile, a few other key players are aiming to invest huge sums for conducting clinical trials to develop state-of-the-art medications.
| Report Attribute | Details |
| Growth Rate | CAGR of 4.9% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Product Type:
Route of Administration:
By Distribution Channel:
By Region:
The global aspirin exacerbated respiratory disease market is projected to exceed US$ 8.7 Billion in 2032.
North America is expected to dominate the aspirin exacerbated respiratory disease market in the near future.
Apotex Corporation, Pfizer Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Cadila Pharmaceuticals are some of the leading companies in the aspirin exacerbated respiratory disease market.
Our Research Products
The "Full Research Suite" delivers actionable market intel, deep dives on markets or technologies, so clients act faster, cut risk, and unlock growth.
The Leaderboard benchmarks and ranks top vendors, classifying them as Established Leaders, Leading Challengers, or Disruptors & Challengers.
Locates where complements amplify value and substitutes erode it, forecasting net impact by horizon
We deliver granular, decision-grade intel: market sizing, 5-year forecasts, pricing, adoption, usage, revenue, and operational KPIs—plus competitor tracking, regulation, and value chains—across 60 countries broadly.
Spot the shifts before they hit your P&L. We track inflection points, adoption curves, pricing moves, and ecosystem plays to show where demand is heading, why it is changing, and what to do next across high-growth markets and disruptive tech
Real-time reads of user behavior. We track shifting priorities, perceptions of today’s and next-gen services, and provider experience, then pace how fast tech moves from trial to adoption, blending buyer, consumer, and channel inputs with social signals (#WhySwitch, #UX).
Partner with our analyst team to build a custom report designed around your business priorities. From analysing market trends to assessing competitors or crafting bespoke datasets, we tailor insights to your needs.
Supplier Intelligence
Discovery & Profiling
Capacity & Footprint
Performance & Risk
Compliance & Governance
Commercial Readiness
Who Supplies Whom
Scorecards & Shortlists
Playbooks & Docs
Category Intelligence
Definition & Scope
Demand & Use Cases
Cost Drivers
Market Structure
Supply Chain Map
Trade & Policy
Operating Norms
Deliverables
Buyer Intelligence
Account Basics
Spend & Scope
Procurement Model
Vendor Requirements
Terms & Policies
Entry Strategy
Pain Points & Triggers
Outputs
Pricing Analysis
Benchmarks
Trends
Should-Cost
Indexation
Landed Cost
Commercial Terms
Deliverables
Brand Analysis
Positioning & Value Prop
Share & Presence
Customer Evidence
Go-to-Market
Digital & Reputation
Compliance & Trust
KPIs & Gaps
Outputs
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Aspirin Drug Market Size and Share Forecast Outlook 2025 to 2035
Disease Resistant Mask Market Analysis - By Type, Material, End-User, Distribution Channel, and Region - Trends, Growth & Forecast 2025 to 2035
Rare Disease Clinical Trials Market Size and Share Forecast Outlook 2025 to 2035
The lung disease therapeutics market is segmented by disease type, treatment type and distribution channel from 2025 to 2035
Rare Disease Gene Therapy Market
Swine Disease Diagnostic Kit Market Size and Share Forecast Outlook 2025 to 2035
Liver Disease Diagnostics Market Size and Share Forecast Outlook 2025 to 2035
Fabry Disease Market Size and Share Forecast Outlook 2025 to 2035
Byler Disease Market
Airway Disease Treatment Market Size and Share Forecast Outlook 2025 to 2035
Celiac Disease Diagnostics Market Analysis - Size, Share & Forecast 2025 to 2035
Shrimps Disease Diagnostics Market Size and Share Forecast Outlook 2025 to 2035
Chronic Disease Management Market Size and Share Forecast Outlook 2025 to 2035
The Addison Disease Testing Market Is Segmented by Test Type, and End User from 2025 To 2035
Pleural Diseases Therapeutics Market – Drug Trends & Future Outlook 2025 to 2035
Crohn’s Disease (CD) Treatment Market Analysis & Forecast by Drug Type, Distribution Channel and Region through 2035
Sandhoff Disease Therapeutics Market Size and Share Forecast Outlook 2025 to 2035
Zoonotic Disease Treatment Market Size and Share Forecast Outlook 2025 to 2035
Wilson’s Disease Diagnostics Market Analysis – Size, Share & Forecast 2023-2033
Infectious Disease Diagnostics Market Size and Share Forecast Outlook 2025 to 2035
Aspirin Exacerbated Respiratory Disease Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
